Revolutionising the treatment of inflammatory lung diseases
Bringing discovery closer to treatments
TianLi Biotech is pioneering the discovery and development of a portfolio of therapeutic drugs to treat chronic and debilitating diseases of the lungs
Our story
Inspired by the Chinese Artist’s masterpiece of the “Sky ladder”, TianLi Biotech is an aspiration to give chronic lung disease sufferers a breath of fresh air, with our logo representing the stairway to prospect.
TianLi Biotech was established in September 2019 as a joint venture between the University of Melbourne and Beijing No.1 Biotechnology Group Co., Ltd.
TianLi Biotech is dedicated to harnessing the modulation of Casein Kinase 1 δ/ε (CK1 δ/ε) to create new therapeutics for idiopathic pulmonary fibrosis and other inflammatory lung diseases.
Our Areas of Focus
We focus on developing new treatments for respiratory inflammatory diseases
where there is an unmet medical need. This includes iodiopathic pulmonary fibrosis (IPF), severe asthma and chronic obstructive pulmonary disease (COPD).
For information on TianLi Biotech and the company development program please contact us via:
info@tlbiotech.com.au
Follow us on LinkedIn
© Copyright 2023 -
TianLi Biotech
Website designed by
Fifth Castle Media